RESUMEN
OBJECTIVE: To investigate the factors related to activation of transforming growth factor-beta 1 (TGF-beta1) at sites of endometriosis. STUDY DESIGN: TGF-beta1 is activated by plasmin, which is formed when plasminogen is activated by urokinase-type plasminogen activator (uPA). We studied these factors by immunohistochemistry or immunoassay. RESULTS: TGF-beta1 protein was localized mainly in the cytoplasm of glandular epithelial cells in both endometriotic cysts and normal endometrium, but strongly positive immunostaining was significantly more common in cysts. The levels of TGF-beta1, uPA and plasmin/alpha2-plasmin inhibitor complex were all higher in cyst fluid than in peritoneal fluid. There was little uPA protein expression in the glandular epithelium of normal endometrium, but it was prominent in the cytoplasm of glandular epithelial cells from endometriotic cysts, and strongly positive immunostaining was significantly more common in cysts. CONCLUSION: These results suggest that TGF-beta1 activity is increased at sites of endometriosis due to enhanced production of both uPA and TGF-beta1 by glandular epithelium and because plasmin activates TGF-beta1 after being converted from plasminogen by uPA.
Asunto(s)
Endometriosis/metabolismo , Fibrinolisina/metabolismo , Quistes Ováricos/metabolismo , Factor de Crecimiento Transformador beta1/metabolismo , Activador de Plasminógeno de Tipo Uroquinasa/metabolismo , Adulto , Distribución de Chi-Cuadrado , Endometriosis/patología , Femenino , Humanos , Inmunoensayo , Inmunohistoquímica , Persona de Mediana Edad , Quistes Ováricos/patología , Estadísticas no ParamétricasRESUMEN
PURPOSE: Identification of cancer/testis antigens useful for diagnosis or immunotherapy of cancers was attempted by cDNA expression cloning with patients' sera (SEREX). EXPERIMENTAL DESIGN: cDNA expression libraries made from testis or endometrial cancer cell lines were screened using sera from patients with endometrial cancer or melanoma patients immunized with dendritic cells pulsed with autologous tum or lysates. Tissue-specific expression by RT-PCR and immunogenicity by Western blotting of the bacterial recombinant antigen with sera from cancer patients were evaluated. RESULTS: A cancer/testis antigen, CAGE, was isolated by two independently performed SEREX. CAGE was expressed in various cancer cell lines including endometrial cancer, colon cancer, and melanoma in 7 of 10 endometrial cancer tissues and in 1 of 3 atypical endometrial hyperplasia, but not in normal tissues including the endometrium and testis. The protein expression on cancer cells was confirmed by Western blot analysis with the recombinant CAGE protein, anti-CAGE IgG antibody was detected in sera from 5 of 45 endometrial cancer, 2 of 24 melanoma, and 2 of 33 colon cancer patients, but not in sera from healthy individuals. By ELISA analysis, anti-CAGE antibody was detected in 12 of 45 endometrial cancer, 2 of 20 melanoma, and 4 of 33 colon cancer patients. Intriguingly, anti-CAGE antibody was highly positive in 7 of the 13 (53.8%) microsatellite instability (MSI)-H patients with endometrial cancer, but negative in 20 non-MSI-H patients (P = 0.001). CONCLUSION: CAGE may be useful for immunotherapy and diagnosis of various cancers particularly MSI-positive endometrial cancer.
Asunto(s)
Neoplasias Endometriales/genética , Neoplasias Endometriales/inmunología , Perfilación de la Expresión Génica , Repeticiones de Microsatélite , Proteínas Nucleares/biosíntesis , Proteínas Nucleares/inmunología , Anticuerpos Antineoplásicos/análisis , Formación de Anticuerpos , Antígenos Nucleares , ARN Helicasas DEAD-box , ADN Complementario/biosíntesis , Diagnóstico Diferencial , Neoplasias Endometriales/diagnóstico , Ensayo de Inmunoadsorción Enzimática , Femenino , Biblioteca de Genes , Humanos , Inmunoterapia , Melanoma/genética , Melanoma/inmunología , Persona de Mediana Edad , Proteínas de Neoplasias , Proteínas Nucleares/análisisRESUMEN
OBJECTIVE: To investigate differences in the biological characteristics of ovarian clear cell adenocarcinoma based on the presence/absence of endometriosis and tumor proliferative activity. METHODS: Stage I ovarian clear cell adenocarcinoma patients were divided into groups with and without endometriosis, and immunohistochemical expression of proliferating cell nuclear antigen was determined in surgical specimens. Then xenograft models of human ovarian clear cell adenocarcinoma with or without human ectopic endometrium were created in severe combined immunodeficiency mice, and tumor growth was assessed from the wet weight and the bromodeoxyuridine uptake. Furthermore, a xenograft model of human endometriosis was made with or without ovarian clear cell adenocarcinoma and cytokine production was investigated. RESULTS: The proliferating cell nuclear antigen labeling index was significantly lower in the tumors of patients with endometriosis compared to the tumors of patients without endometriosis. In tumor-bearing mice, the tumor weight and bromodeoxyuridine uptake were both significantly lower when ovarian clear cell adenocarcinoma was associated with endometriosis than in its absence. Release of transforming growth factor-beta1 and interleukin-6 from the ectopic human endometrium was greater in the presence of clear cell adenocarcinoma than without it, and transforming growth factor-beta1 levels showed a significant difference. CONCLUSION: The proliferative activity of early ovarian clear cell adenocarcinoma seems to depend on the association of this cancer with endometriosis. When endometriosis is associated with ovarian clear cell adenocarcinoma, there is a change of its cytokine production that may inhibit tumor growth.
Asunto(s)
Adenocarcinoma de Células Claras/fisiopatología , Proliferación Celular , Endometriosis/complicaciones , Endometriosis/fisiopatología , Neoplasias Ováricas/fisiopatología , Antígeno Nuclear de Célula en Proliferación/análisis , Adenocarcinoma de Células Claras/química , Adenocarcinoma de Células Claras/complicaciones , Adenocarcinoma de Células Claras/patología , Animales , Bromodesoxiuridina/metabolismo , Endometriosis/metabolismo , Endometriosis/patología , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Inmunohistoquímica , Interleucina-6/análisis , Ratones , Ratones SCID , Estadificación de Neoplasias , Neoplasias Ováricas/química , Neoplasias Ováricas/complicaciones , Neoplasias Ováricas/patología , Factor de Crecimiento Transformador beta1/análisis , Trasplante Heterólogo , Factor de Necrosis Tumoral alfa/análisisRESUMEN
In the present study, the fatty acid composition of bone marrow aspirates and serum phospholipids in nine patients with hematologic diseases was investigated, and the effect of fatty acids on osteoblast differentiation in ST2 cells was examined. The concentrations of oleic acid and palmitic acid were significantly higher in bone marrow aspirates than in serum phospholipids, but the concentrations of other fatty acids did not differ. The rate of alkaline phosphatase positive ST2 cells induced by BMP2 was significantly increased by oleic acid, but was unaffected by the presence or absence of palmitic acid. We conclude that the fatty acid composition of bone marrow aspirates differs from that of serum phospholipids. This difference may affect osteoblast differentiation in the bone marrow microenvironment.
Asunto(s)
Médula Ósea/química , Ácidos Grasos/análisis , Adipocitos/citología , Adipocitos/efectos de los fármacos , Adulto , Anciano , Anciano de 80 o más Años , Animales , Médula Ósea/patología , Diferenciación Celular/efectos de los fármacos , Línea Celular , Ácidos Grasos/sangre , Femenino , Enfermedades Hematológicas/sangre , Enfermedades Hematológicas/metabolismo , Enfermedades Hematológicas/patología , Humanos , Ratones , Persona de Mediana Edad , Ácido Oléico/farmacología , Osteoblastos/citología , Osteoblastos/efectos de los fármacos , Ácido Palmítico/farmacología , Fosfolípidos/sangre , Fosfolípidos/químicaRESUMEN
Integration of the human papillomavirus (HPV) genome is thought to be one of the causes of cancer progression. However, there is controversy concerning the physical status of HPV 16 in premalignant cervical lesions, and there have been no reports on the concordance between detection of the integrated form of HPV16 by real-time PCR and by in situ hybridization. We investigated specimens of cervical intraepithelial neoplasia (CIN) and invasive carcinomas for the physical status of HPV 16 by real-time PCR and in situ hybridization. The presence of the integrated form was detected by both real-time PCR and in situ hybridization in zero of four cases of CIN1, three of six cases of CIN2, nine of 27 cases of CIN3, and two of six cases of invasive carcinomas. Integrated HPV 16 was present in some premalignant lesions but was not always present in carcinomas. The concordance rate between the two methods for the detection of the presence of the integrated form was 37 of 43 (86%) cases. Real-time PCR and in situ hybridization were found to be complementary and convenient techniques for determining the physical status of the HPV genome. We conclude that a combination of both methods is a more reliable means of assessing the physical status of the HPV genome in cervical neoplasia.
Asunto(s)
Carcinoma/virología , Hibridación in Situ , Papillomaviridae/aislamiento & purificación , Infecciones por Papillomavirus/diagnóstico , Reacción en Cadena de la Polimerasa/métodos , Displasia del Cuello del Útero/virología , Neoplasias del Cuello Uterino/virología , Carcinoma/genética , Carcinoma/patología , ADN Viral/análisis , Femenino , Genoma Viral , Humanos , Papillomaviridae/genética , Neoplasias del Cuello Uterino/genética , Neoplasias del Cuello Uterino/patología , Integración Viral/genética , Displasia del Cuello del Útero/genética , Displasia del Cuello del Útero/patologíaRESUMEN
In vitro anticancer drug sensitivity tests have been performed for various types of cancers, and a relationship with clinical response has been observed. The collagen gel droplet-embedded culture drug sensitivity test (CD-DST) is a new in vitro anticancer drug sensitivity test by Yabushita et al., recently reported to be useful in ovarian cancer. CD-DST allows analysis of a small number of cells, compared to other anticancer drug sensitivity tests. Here, we report a successful analysis of anticancer drug sensitivity by CD-DST using cancerous ascites and pleural fluid samples from 2 patients with advanced ovarian cancer. To our knowledge, this is only the second report of the application of CD-DST in ovarian cancer, and our results suggest that CD-DST could be helpful in the selection of anticancer drugs for neoadjuvant chemotherapy in advanced ovarian cancer.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Ensayos de Selección de Medicamentos Antitumorales/métodos , Neoplasias Ováricas/tratamiento farmacológico , Neoplasias Ováricas/patología , Protocolos de Quimioterapia Combinada Antineoplásica/farmacología , Ascitis/patología , Camptotecina/administración & dosificación , Camptotecina/análogos & derivados , Camptotecina/farmacología , Cisplatino/administración & dosificación , Cisplatino/farmacología , Docetaxel , Doxorrubicina/administración & dosificación , Doxorrubicina/farmacología , Femenino , Humanos , Irinotecán , Persona de Mediana Edad , Recurrencia Local de Neoplasia/tratamiento farmacológico , Recurrencia Local de Neoplasia/patología , Paclitaxel/administración & dosificación , Paclitaxel/farmacología , Derrame Pleural Maligno/patología , Taxoides/administración & dosificación , Taxoides/farmacologíaRESUMEN
PURPOSE: Although many articles have been published regarding chromosomal instability (CI) and microsatellite instability (MI) in endometrial adenocarcinoma, the relationship between prognostic factors and the biological mechanisms accounting for genetic instability in these tumors has not yet been precisely defined. To do that, it will be necessary to clarify the molecular mechanisms involved in endometrial carcinogenesis. EXPERIMENTAL DESIGN: Tissue samples from 43 human primary endometrioid endometrial adenocarcinomas (EACs) were analyzed for CI and MI status using comparative genomic hybridization and 11 microsatellite loci, respectively. Methylation status of the promoter of MLH1 was also determined. We analyzed all three of these parameters in relation to each other and to clinicopathological factors. RESULTS: Sixty-five percent of the EACs we examined had detectable CI. Frequent copy number gains were seen at 1q25-41 (23%), 8q11.1-q21.1 (23%), 8q21.3-qter (21%); 28% of these tumors exhibited high-frequency MI (MSI-H); Methylation of the MLH1 promoter was observed in 92% of EACs with MSI-H. Southern blotting showed amplification of MYCN in one tumor, which has been documented for the first time in a primary human EAC. CONCLUSIONS: MSI-H was correlated with histological grade, International Federation of Gynecologists and Obstetricians (FIGO) stage, myometrial invasion, and lymphonode metastasis. Our comparative genomic hybridization results demonstrated that the number of chromosomes involved in genomic alterations in EACs was distinctively fewer than those in other types of tumor. The carcinogenetic process leading to EAC appears to be highly complex; for example, MI and CI may act synergistically, whereas CI and/or MI are likely to be linked with tumor heterogeneity.
Asunto(s)
Neoplasias Endometriales/genética , Repeticiones de Microsatélite/genética , Proteínas Adaptadoras Transductoras de Señales , Adulto , Anciano , Proteínas Portadoras , Metilación de ADN , Reparación del ADN/genética , Neoplasias Endometriales/mortalidad , Neoplasias Endometriales/patología , Femenino , Humanos , Persona de Mediana Edad , Homólogo 1 de la Proteína MutL , Invasividad Neoplásica , Proteínas de Neoplasias/genética , Estadificación de Neoplasias , Proteínas Nucleares , Hibridación de Ácido Nucleico/métodos , Pronóstico , Regiones Promotoras Genéticas/genética , Insuficiencia del TratamientoRESUMEN
PURPOSE: Human papillomavirus (HPV) infections are associated with cervical neoplasia. Cellular and viral proteins are known to interact with the papillomavirus E2 protein to initiate transcription and DNA replication in the HPV life cycle. Our aim was to identify peptides that bind to the HPV16 E2 protein and thereby inhibit its ability to alter the transcriptional activity of other genes. EXPERIMENTAL DESIGN: The HPV16 E2 protein was expressed and purified to near homogeneity in bacteria. We screened a phage display library of random peptides for ones that bound to HPV16 E2 protein. Among the isolated phage clones, we found that tryptophan-rich peptide sequences appeared repetitively in successive cycles of phage library panning. Replacement of the tryptophan amino acids in these dodecapeptides reduced the degree to which these peptides bound to the E2 protein. These E2-binding peptides were tested for their ability to inhibit the transcriptional regulatory function of E2 in a test cell line, which contained an E2 gene and a luciferase reporter gene driven by an E2-dependent transcriptional promoter. RESULTS: Delivery of four of the E2 binding peptides into the intracellular compartment of the test cell line resulted in suppression of the E2-dependent luciferase expression. Deletion of the tryptophan residues from these peptides reduced their E2 binding and their ability to suppress E2-dependent luciferase expression in the test cell line. CONCLUSIONS: These results suggest a strategy for the development of chemical inhibitors of E2-dependent transcription of viral genes in HPV-infected cells as an approach to the therapy of chronic HPV infections.
Asunto(s)
Proteínas de Unión al ADN , Regulación Viral de la Expresión Génica , Proteínas Oncogénicas Virales/metabolismo , Fragmentos de Péptidos/farmacología , Transcripción Genética/efectos de los fármacos , Proteínas Virales/antagonistas & inhibidores , Células Cultivadas , Replicación del ADN/efectos de los fármacos , ADN Viral/antagonistas & inhibidores , ADN Viral/metabolismo , Humanos , Luciferasas/metabolismo , Mutagénesis Sitio-Dirigida , Proteínas Oncogénicas Virales/genética , Papillomaviridae/efectos de los fármacos , Papillomaviridae/fisiología , Fragmentos de Péptidos/metabolismo , Biblioteca de Péptidos , Triptófano/química , Triptófano/metabolismo , Proteínas Virales/genética , Proteínas Virales/metabolismo , Replicación Viral/efectos de los fármacosRESUMEN
PURPOSE: Although tumor stage is considered a prognosticfeature for ovarian clear cell adenocarcinomas (OCCAs), it is not likely to fully account for the clinical and biological variability characteristic of the disease. The aim of this study was to investigate aberrations of DNA copy number in OCCA tumors and identify genetic markers that would increase our understanding of the pathogenesis of OCCA and assist in more accurately predicting the outcome for an individual patient with this disease. EXPERIMENTAL DESIGN: We determined copy number aberrations among 20 primary OCCA tumors by means of comparative genomic hybridization and investigated their relationship to clinicopathological data. We also measured expression levels of candidate target genes within critical regions by quantitative real-time reverse transcription-PCRs and compared those data with copy number status and patient outcomes. RESULTS: We identified several nonrandom chromosomal aberrations among the 20 primary OCCA tumors examined. Among them, gain of DNA at 17q21-q24 showed significantly negative correlation with disease-free and overall survival (P = 0.0012 and 0.0039, respectively, log-rank test). This correlation held even for patients with stage I tumors. Among 15 candidate genes within the 17q21-q24 region, we found significantly elevated expression of PPM1D and APPBP2, and their heightened expression correlated negatively with disease-free survival (P = 0.0090, log-rank test adjusted for multiple comparisons). CONCLUSIONS: Information gained from our relatively large panel of OCCA tumors suggested that 17q21-q24 gain and consequent overexpression of two potential targets, PPM1D and APPBP2, are associated with malignant phenotypes of this tumor and may be useful predictors for prognosis.
Asunto(s)
Adenocarcinoma de Células Claras/genética , Aberraciones Cromosómicas , Cromosomas Humanos Par 17 , Proteínas Asociadas a Microtúbulos/genética , Proteínas de Neoplasias/genética , Neoplasias Ováricas/genética , Fosfoproteínas Fosfatasas/genética , Adenocarcinoma de Células Claras/mortalidad , Adenocarcinoma de Células Claras/patología , Adulto , Femenino , Dosificación de Gen , Humanos , Persona de Mediana Edad , Estadificación de Neoplasias , Neoplasias Ováricas/mortalidad , Neoplasias Ováricas/patología , Pronóstico , Proteína Fosfatasa 2CRESUMEN
PURPOSE: The purpose of this research was to generate a human monoclonal antibody specific to gynecological cancers and to evaluate such an antibody as therapy for gynecological cancers. EXPERIMENTAL DESIGN: Transchromosomal KM mice were immunized with the human uterine endometrial cancer cell line SNG-S. Hybridomas were constructed between spleen cells from KM mice and mouse myeloma cells. Reactivity of the antibody was evaluated by immunohistochemistry of pathological specimens of gynecological cancers. Cytotoxicity of HMMC-1 against SNG-S cells was tested by in vitro cytotoxicity assays. The epitope of HMMC-1 was determined by transfection with a panel of glycosyltransferase cDNAs and by inhibition assays with chemically synthesized oligosaccharides. RESULTS: HMMC-1 is a human IgM monoclonal antibody that reacts positively with mullerian duct-related carcinomas with positive rates of 54.6% against uterine endometrial adenocarcinoma, 76.9% against uterine cervical adenocarcinoma, and 75.0% against epithelial ovarian cancer. HMMC-1 does not react with normal endometrium at proliferative or secretory phases, normal uterine cervix, or normal and malignant tissue from other organs, whereas it reacts weakly with the epithelium of the gall bladder and the collecting duct of the kidney. HMMC-1 exhibits antigen-dependent and complement-mediated cytotoxicity. Upon cotransfection with cDNAs encoding two glycosyltransferases required for fucosylated extended core 1 O-glycan, mammalian cells express HMMC-1 antigen. Finally, binding of HMMC-1 to SNG-S cells is inhibited by synthetic Fucalpha1-->2Galbeta1-->4GlcNAcbeta1-->3Galbeta1-->3GalNAcalpha1-octyl. CONCLUSIONS: These results indicate that HMMC-1 specifically recognizes a novel O-glycan structure. The unique specificity and cytotoxicity of HMMC-1 strongly suggest a therapeutic potential of this antibody.
Asunto(s)
Anticuerpos Monoclonales/inmunología , Carcinoma/inmunología , Neoplasias de los Genitales Femeninos/inmunología , Inmunoglobulina M/inmunología , Conductos Paramesonéfricos/patología , Animales , Anticuerpos Monoclonales Humanizados , Carcinoma/patología , ADN Complementario/análisis , Femenino , Neoplasias de los Genitales Femeninos/patología , Glicosiltransferasas/genética , Humanos , Hibridomas , Inmunohistoquímica , Ratones , Mieloma Múltiple/patología , Bazo/citología , Células Tumorales CultivadasRESUMEN
We provide a detailed explanation of the procedure of the histoculture drug response assay (HDRA) with 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) end point among several modified HDRA procedures. Fresh surgical specimens are cut into approx 1- to 2-mm3 pieces and put on a gelatin sponge infiltrated with culture medium containing a test drug. After incubation for 7 d, cell viability is assessed by the MTT assay. HDRA uses cancer tissue fragments with cells growing in three dimensions, with maintenance of intercellular contact and interactions with stromal cells. Therefore, it seems that HDRA can assess the sensitivity of tumor cells to anticancer drugs in conditions similar to those in vivo and, consequently, shows high prediction rate.
Asunto(s)
Antineoplásicos/farmacología , Sales de Tetrazolio , Tiazoles , Biopsia , Supervivencia Celular/efectos de los fármacos , Colorantes , Ensayos de Selección de Medicamentos Antitumorales , Femenino , Gelatina , Geles , Humanos , Neoplasias Ováricas/patología , Técnicas de Cultivo de TejidosRESUMEN
A cell line, designated as RMG-V, was established from a patient with clear cell adenocarcinoma of the ovary. The cell line has grown without interruption and has been propagated continuously by serial passaging (more than 36 times) over 5 years. The cells are spindle-shaped, display neoplastic and pleomorphic features, and grow in a jigsaw puzzle-like arrangement while forming monolayers without contact inhibition. These cells proliferate rapidly, and the population doubling time is about 15.5 hours. The number of chromosomes ranges between 77 and 85, with a modal number of 83.
Asunto(s)
Adenocarcinoma de Células Claras/patología , Proliferación Celular , Neoplasias Ováricas/patología , Adenocarcinoma de Células Claras/genética , Línea Celular Tumoral , Cromosomas Humanos/genética , Femenino , Humanos , Cariotipificación , Persona de Mediana Edad , Neoplasias Ováricas/genética , Factores de TiempoRESUMEN
One hundred and eighty-five Japanese women with cervical intraepithelial neoplasia (CIN) were enrolled in this follow-up study. On the basis of the prevalence of human papillomavirus (HPV) DNA in Japanese cervical cancer patients, HPV types were categorized into three groups as follows: (1) high risk (types 16, 18, 33, 52, and 58), (2) intermediate risk (types 31, 35, 39, 51, 56, 59, 68, and 70), (3) low risk (type 6, 30, 42, 53, 54, 55, 66 and unclassified types). High-risk HPV infection was a risk factor for progression of the disease. The regression rate in the HPV negative group was higher (83.3%) than those in the HPV positive groups, but the differences in regression were no longer significant after adjustment for age and CIN grade. It is also noted that a lower cytomegalovirus IgG level and a smaller number of past pregnancies might be associated with the regression of CIN lesions.
Asunto(s)
Displasia del Cuello del Útero/diagnóstico , Displasia del Cuello del Útero/epidemiología , Estudios de Cohortes , Progresión de la Enfermedad , Femenino , Humanos , Japón/epidemiología , Estadificación de Neoplasias , Papillomaviridae/clasificación , Papillomaviridae/aislamiento & purificación , Paridad , Pronóstico , Modelos de Riesgos Proporcionales , Factores de Riesgo , Conducta Sexual , Fumar , Resultado del Tratamiento , Displasia del Cuello del Útero/patología , Displasia del Cuello del Útero/virologíaRESUMEN
The serum level of beta1,4-galactosyltransferase (beta1,4-GalT) is increased in both malignancy and benign diseases. Galactosyltransferase associated with tumor (GAT) is one of the soluble forms of beta1,4-GalT, and is a marker of ovarian cancer with a high specificity. GAT and normal soluble beta1,4-GalT are both derived from the same membrane-bound form of the enzyme. This study investigated the mechanism of GAT elevation in patients with ovarian cancer. The serum levels of GAT and normal beta1,4-GalT were measured using specific monoclonal antibodies. In addition, nude mice bearing human ovarian cancer were used to assess the kinetics of tumor-derived enzymes. GAT and normal beta1,4-GalT were both detected in ovarian cancer patients, but only GAT reflected the tumor status. In tumor-bearing nude mice, both soluble forms of beta1,4-GalT were released from tumor cells, but the half-life of GAT was far shorter than that of normal beta1,4-GalT. Addition of serum from healthy women to colostrum (which has a high GAT content) reduced the GAT level, while adding patient serum caused a significantly smaller reduction of GAT. Addition of the serum from mouse which includes no human beta1,4-GalT to colostrum also reduced the GAT level with no significant change of total soluble beta1,4-GalT. These findings indicate that human serum contains certain factors that decrease the GAT level, but these factors are inhibited in ovarian cancer patients so that a high GAT level persists. It seems that the decrease of GAT occurs as a result of conversion into normal beta1,4-GalT.
Asunto(s)
Biomarcadores de Tumor/sangre , N-Acetil-Lactosamina Sintasa/sangre , Neoplasias Ováricas/enzimología , Animales , Biomarcadores de Tumor/genética , Northern Blotting , Calostro/enzimología , Femenino , Galactosiltransferasas/sangre , Galactosiltransferasas/genética , Humanos , Técnicas para Inmunoenzimas , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Persona de Mediana Edad , N-Acetil-Lactosamina Sintasa/genética , Neoplasias Experimentales/enzimología , ARN Mensajero/metabolismo , Células Tumorales CultivadasRESUMEN
Carcinogenesis of cervical cancer has been investigated, and p16(INK4a) overexpression in squamous cell carcinoma of the cervix has been reported as a result of infection by human papillomavirus (HPV) (eg, HPV 16), and the consequence of the retinoblastoma (Rb) protein inactivation by HPV E7 protein. However, to our knowledge, there have been no studies on the relation between p16(INK4a) overexpression associated with HPV and small cell carcinoma of the cervix, which behaves more aggressively clinically than squamous cell carcinoma. The purpose of this study was to determine whether p16(INK4a) is overexpressed in small cell carcinoma, and if p16(INK4a) is overexpressed, the types of HPV that are related to this cancer. We reviewed 10 cases of small cell carcinoma and examined them for p16(INK4a) overexpression by immunohistochemistry. We also performed HPV typing with polymerase chain reaction (PCR)-sequencing analysis and in situ hybridization and found that p16(INK4a) was overexpressed in every case. PCR-sequencing analyses revealed that all cases were HPV-positive and that 9 cases were positive for HPV 18. Five of the 9 cases positive for HPV 18 were also positive by in situ hybridization and yielded a punctate signal, considered to represent the integrated form. In conclusion, p16(INK4a) was overexpressed and HPV 18 was frequently detected in an integrated form in small cell carcinoma. Therefore, inactivation of Rb protein by HPV 18 E7 protein may be associated with carcinogenesis of small cell carcinoma the same as inactivation of Rb protein by HPV 16 E7 protein is associated with carcinogenesis of squamous cell carcinoma.
Asunto(s)
Carcinoma de Células Pequeñas/metabolismo , Inhibidor p16 de la Quinasa Dependiente de Ciclina/metabolismo , Infecciones por Papillomavirus/metabolismo , Infecciones Tumorales por Virus/metabolismo , Neoplasias del Cuello Uterino/metabolismo , Adulto , Anciano , Biomarcadores de Tumor/metabolismo , Carcinoma de Células Pequeñas/secundario , Carcinoma de Células Pequeñas/virología , ADN Viral/análisis , Femenino , Humanos , Técnicas para Inmunoenzimas , Hibridación in Situ , Persona de Mediana Edad , Estadificación de Neoplasias , Papillomaviridae/clasificación , Papillomaviridae/genética , Papillomaviridae/aislamiento & purificación , Infecciones por Papillomavirus/patología , Reacción en Cadena de la Polimerasa , Infecciones Tumorales por Virus/patología , Neoplasias del Cuello Uterino/patología , Neoplasias del Cuello Uterino/virologíaRESUMEN
OBJECTIVE: To gain insight into the characteristics and current status of climacteric symptoms reported by middle-aged and older women in Japan, we surveyed women presenting at our menopause clinic. DESIGN: The participants included 1,069 women, ranging in age from 40 to less than 60 years (mean age, 50.2 y). Climacteric (indefinite) symptoms were objectively assessed with the use of the Keio questionnaire, which grades the severity of 40 types of symptoms classified into 20 subgroups. The total scores obtained for the 40 symptoms were used to calculate symptom prevalence and severity. To evaluate ovarian function, concentrations of estradiol and follicle-stimulating hormone (FSH) in sera were measured. RESULTS: The most frequent symptom was general fatigue, reported by 88.2% of the women. Shoulder stiffness was the symptom rated to be severe by the highest percentage of women (38.1%). The prevalence and severity of hot flushes (and sweats) were slightly higher in perimenopausal and early postmenopausal women than in premenopausal and late postmenopausal women. The prevalence and severity of hot flushes and sweats were higher in women with estradiol < 25 pg/mL and FSH > 40 mIU/mL than in those with estradiol > or = 25 pg/mL and FSH < or = 40 mIU/mL. CONCLUSION: General fatigue and shoulder stiffness, symptoms with low hormone dependence, are the two most frequent climacteric symptoms in our clinic. Hot flushes and sweats, symptoms with high hormone dependence, are also common symptoms.
Asunto(s)
Sofocos/epidemiología , Menopausia , Adulto , Estradiol/sangre , Femenino , Hormona Folículo Estimulante/sangre , Sofocos/sangre , Sofocos/etiología , Sofocos/patología , Humanos , Japón/epidemiología , Persona de Mediana Edad , Prevalencia , Índice de Severidad de la Enfermedad , Encuestas y CuestionariosRESUMEN
Endometrial cancer is the second most common malignancy in patients with hereditary nonpolyposis colorectal cancer (HNPCC). This cancer is caused by germline mutations in one of the DNA mismatch repair (MMR) genes. The present study was undertaken to analyze the relation between microsatellite instability (MSI) and germline mutations of MMR genes. We analyzed MSI in 38 cases of endometrial cancer. MSI was present in one or more (out of 5 examined) regions in 11 (29%) cases. Furthermore, alterations in MLH1 and MSH2, two culprit genes representative of HNPCC, were examined in the 11 MSI-positive patients using polymerase chain reaction-single-strand conformation polymorphism and sequencing. Germline mutations, namely, 1) a missense mutation at codon 688 (ATG-->ATA, Met-->Ile) and 2) a missense mutation at codon 390 (CTT-->TTT, Leu-->Phe) of the MSH2 gene, were found in 2 of the 11 patients (18%). Although these two cases do not fulfill the new Amsterdam criteria, they had strong family histories of colorectal and endometrial carcinoma. Our results show that genetic testing is important in cases of endometrial cancer with a history suggestive of HNPCC even if the new Amsterdam criteria are not fulfilled.
Asunto(s)
Neoplasias Colorrectales Hereditarias sin Poliposis/genética , Proteínas de Unión al ADN , Neoplasias Endometriales/genética , Mutación , Proteínas Proto-Oncogénicas/genética , Proteínas Adaptadoras Transductoras de Señales , Adulto , Anciano , Anciano de 80 o más Años , Proteínas Portadoras , Reparación del ADN/genética , Femenino , Humanos , Masculino , Repeticiones de Microsatélite , Persona de Mediana Edad , Homólogo 1 de la Proteína MutL , Proteína 2 Homóloga a MutS , Proteínas de Neoplasias/genética , Proteínas Nucleares , LinajeRESUMEN
beta-1,4-galactosyltransferase (beta-1,4-GT) has been reported to be activated in ovarian carcinoma cells and an isoform of this enzyme has been used as a tumor marker for ovarian cancer. The present study was undertaken to clarify how beta-1,4-GT affected the cell biological characteristics of ovarian cancer. To this end, we transfected an ovarian tumor cell line with an antisense gene of beta-1,4-GT. Proliferative potential and morphology of the cells transfected with the antisense gene did not differ from those of the control cells. Adhesive potential to the constituents of extracellular matrix was reduced in the antisense gene transfectants. In a nude mouse, the number of peritoneal dissemination foci of the antisense transfectants was smaller than that of the control cells. These results indicated that beta-1,4-GT is closely related to the invasive and metastatic potentials of ovarian cancer while it is not involved in the proliferative potential.
Asunto(s)
N-Acetil-Lactosamina Sintasa/genética , Neoplasias Ováricas/enzimología , Neoplasias Ováricas/genética , Animales , Northern Blotting , Southern Blotting , Adhesión Celular , División Celular , Línea Celular Tumoral , ADN Complementario/metabolismo , Matriz Extracelular/metabolismo , Femenino , Humanos , Ratones , Ratones Desnudos , Metástasis de la Neoplasia , Trasplante de Neoplasias , Oligonucleótidos Antisentido/farmacología , Isoformas de Proteínas , TransfecciónRESUMEN
A number of previously published studies have suggested that blood-group-related carbohydrate antigens, expressed on cancer cell membranes, may be related to the cytobiological characteristics (invasiveness, metastasizing potential, etc.) of cancer. In our previous study, we divided SNG-II, a human endometrial cancer cell line, into SNG-S and SNG-W and compared their properties. In that study, we found that H type 1 carbohydrate antigen, which is scarcely expressed on SNG-S but strongly expressed on SNG-W, may play a significant role in the adhesion of SNG-W to vascular endothelial cells. In the present study, we clarified in some detail, the relationship between H type 1 carbohydrate antigen and endothelial cell adhesion, and also compared the propensity for hematogenous metastasis of these two cell lines in vivo. The following results were obtained: 1. The adhesion of SNG-W to human umbilical vein endothelial cells (1), was inhibited in a concentration-dependent manner by the addition of one H type 1 monoclonal antibody. 2. In the flow cytometric analysis using single carbohydrate-conjugated fluorescent beads, it was shown that H type 1 carbohydrate-attached beads adhered to HUVECs. On the other hand, beads conjugated with Lewis, Lewis, or H type 2 carbohydrate antigen did not adhere to HUVECs. 3. In an in vivo study using a nude mouse model of lung metastasis, SNG-W was found to show a significantly greater propensity for blood-borne metastasis than SNG-S. These results suggest that the H1 carbohydrate antigen expressed on the cancer cell membrane serves as an adhesion factor for vascular endothelial cells, and that endometrial cancer expressing high levels of this antigen has a high propensity for blood-borne metastasis, suggesting that the expression of this antigen on the cancer cells may serve as an indicator of poor prognosis.
Asunto(s)
Sistema del Grupo Sanguíneo ABO/fisiología , Moléculas de Adhesión Celular/fisiología , Neoplasias Endometriales/patología , Endotelio Vascular/metabolismo , Sistema del Grupo Sanguíneo ABO/inmunología , Animales , Anticuerpos Monoclonales/farmacología , Adhesión Celular , Moléculas de Adhesión Celular/inmunología , Células Cultivadas/citología , Células Cultivadas/metabolismo , Endotelio Vascular/citología , Femenino , Citometría de Flujo , Humanos , Antígenos del Grupo Sanguíneo de Lewis/fisiología , Neoplasias Pulmonares/inmunología , Neoplasias Pulmonares/secundario , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Microesferas , Ácido N-Acetilneuramínico/química , Metástasis de la Neoplasia , Células Neoplásicas Circulantes , Células Tumorales Cultivadas/citología , Células Tumorales Cultivadas/metabolismoRESUMEN
BACKGROUND: To clarify the pathogenicity of multiple human papilloma virus (HPV) infection, we applied SSCP (single-strand DNA conformation polymorphism) analysis for cervical neoplastic lesions. MATERIALS AND METHODS: Two hundred and sixty-six cervical swab specimens from normal cervix (n=64), cervical dysplasia (n=95), carcinoma in situ (n=79) and cervical cancer (n=28), were studied by nested PCR-SSCP analysis using L1 consensus primers. RESULTS: In 95 samples of cervical dysplasia, HPV infection was detected in 98.9% (94 out of 95), multiple HPV infection was detected in 38.3% (36 out of 94). In 19 squamous cell carcinomas (SCC) and 9 adenocarcinomas, the detection rate of HPV infection was 84.2% (16 out of 19) and 55.6% (5 out of 9), respectively, and all HPV-positive cases showed infection of a single HPV, among which HPV 16 occupied 68.6% (11 out of 16) in SCC and HPV 18 occupied 100% (5 out of 5) in adenocarcinoma. CONCLUSION: Multiple HPV infections may be concerned with pathogenicity in cervical dysplasia; however, the single infection with only a few HPV types, such as type 16 in SCC and type 18 in adenocarcinoma, may play a role in cervical carcinogenesis.